In pharmaceutical development, formulation stability is often discussed only in terms of excipient selection and process optimization. However, in real-world product development, stability is achieved through an integrated approach involving formulation, process, and packaging together.
Packaging is not merely a container. It is a functional component of the drug product designed to protect the formulation from environmental stress factors such as moisture, oxygen, light, and volatile loss.
Many degradation pathways originate externally rather than internally. Hydrolysis, oxidation, and photodegradation frequently occur due to exposure during storage, transportation, and patient use.
In such cases, appropriate packaging selection becomes a scientifically justified risk-mitigation strategy rather than a corrective shortcut.
Moisture-sensitive formulations such as effervescent tablets, orally disintegrating tablets, and hygroscopic APIs often demonstrate improved stability when protected using high-barrier packaging systems like Alu–Alu blisters or HDPE containers with desiccants.
Oxygen-sensitive drug products, including lipid-based systems and oxidation-prone APIs, can be stabilized through nitrogen flushing, oxygen scavengers, and materials with low oxygen transmission rates.
Light-sensitive drugs such as nifedipine, riboflavin, and furosemide require amber containers or UV-protective blister films to prevent photodegradation.
Under ICH Q8, packaging is considered part of the overall pharmaceutical design and may be treated as a material attribute contributing to the control strategy when supported by risk assessment and stability data.
Regulatory agencies accept stabilization through packaging provided the formulation is pharmaceutically sound, degradation risks are scientifically understood, and stability data demonstrates consistent product quality throughout shelf life.
Packaging should not be used to mask fundamental formulation instability. Instead, it should be applied as a deliberate, risk-based control to protect a well-designed product from unavoidable environmental exposure.
In practice, formulation development does not end at the blender or coating pan. True product robustness is achieved only when formulation, process, and packaging are scientifically aligned.
A well-justified packaging strategy often becomes the final step that converts a laboratory-stable formulation into a commercially reliable medicine.
Formulation stability is not achieved by formulation alone. It is achieved by designing packaging as well.
Read also: Pharmaceutical QA for Packaging and Labeling Controls
Resource Person: Moinuddin Syed. Ph.D, PMP®